Found 27 Anemia trials
A listing of Anemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety.
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines MK-4830 in combination with pembrolizumab in participants with PD-L1 positive NSCLC.
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
This is a screening study to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
the purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). Eligible subjects will be those with NSCLC.
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.Participants for …
The Investigation Device Exemption (IDE) study will evaluate the safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
This study aims to provide much-needed data regarding how to optimally treat vulnerable older adults with metastatic NSCLC.
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. We would like to rely on Advarra as the IRB …
This study compares the impact of using a combination of drugs, ramucirumab and pembrolizumab, versus standard chemotherapy for treating advanced non-small cell lung cancer that is stage IV or recurrent. Ramucirumab blocks new blood vessel growth that tumors need, while pembrolizumab boosts the immune system to fight cancer. The trial …
